Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

<h4>Background</h4> <p>The EQUATOR trial investigated the efficacy and safety of filgotinib, a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of psoriatic arthritis (PsA).</p> <h4>Methods</h4> <p>This completed, randomised, double-blind, place...

Full description

Bibliographic Details
Main Authors:	Mease, P, Coates, L, Helliwell, P, Stanislavchuk, M, Rychlewska-Hanczewska, A, Dudek, A, Abi-Saab, W, Tasset, C, Meuleners, L, Harrison, P, Besuyen, R, Van Der Aa, A, Mozaffarian, N, Greer, J, Kunder, R, Van Den Bosch, F, Gladman, D
Format:	Journal article
Published:	Elsevier 2018

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

Similar Items